The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Open accessAbstract
BACKGROUND: Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute effective treatment for ulcerative colitis. METHODS: We conducted two integrated randomized, double-blind, placebo-controlled trials of vedolizumab in patients with active disease. In the trial of induction therapy, 374 patients (cohort 1) received vedolizumab (at a dose of 300 mg) or placebo intravenously at weeks 0 and 2, and 521 patients (cohort 2) received open-label vedolizumab at weeks 0 and 2, with disease evaluation at week 6. In the trial of maintenance therapy, patients in either cohort who had a response to vedolizumab at week 6 were randomly assigned to continue receiving vedolizumab every 8 or 4 weeks or to switch to placebo for up to 52 weeks. A response was defined as a reduction in the Mayo Clinic score (range, 0 to 12, with higher scores indicating more active disease) of at least 3 points and a decrease of at least 30% from baseline, with an accompanying decrease in the rectal bleeding subscore of at least 1 point or an absolute rectal bleeding subscore of 0 or 1. RESULTS: Response rates at week 6 were 47.1% and 25.5% among patients in the vedolizumab group and placebo group, respectively (difference with adjustment for stratification factors, 21.7 percentage points; 95% confidence interval [CI], 11.6 to 31.7; P<0.001). At week 52, 41.8% of patients who continued to receive vedolizumab every 8 weeks and 44.8% of patients who continued to receive vedolizumab every 4 weeks were in clinical remission (Mayo Clinic score ≤2 and no subscore >1), as compared with 15.9% of patients who switched to placebo (adjusted difference, 26.1 percentage points for vedolizumab every 8 weeks vs. placebo [95% CI, 14.9 to 37.2; P<0.001] and 29.1 percentage points for vedolizumab every 4 weeks vs. placebo [95% CI, 17.9 to 40.4; P<0.001]). The frequency of adverse events was similar in the vedolizumab and placebo groups. CONCLUSIONS: Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis. (Funded by Millennium Pharmaceuticals; GEMINI 1 ClinicalTrials.gov number, NCT00783718.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,902
Self-citationTuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
Schroeder, K. W., Tremaine, W. J., & Ilstrup, D. M. (1987) · New England Journal of Medicine · doi:10.1056/nejm198712243172603 · Cited by 3,026
Ford Alexander, C., Paul, M., Hanauer Steven, B., 谭蓓, & Dong, W. Z. (2001) · Cited by 3,020
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Self-citationMore powerful procedures for multiple significance testing
Hochberg, Y., & Benjamini, Y. (1990) · Statistics in Medicine · doi:10.1002/sim.4780090710 · Cited by 2,715
The Medical Dictionary for Regulatory Activities (MedDRA)
Brown, E. G., Wood, L., & Wood, S. (1999) · Drug Safety · doi:10.2165/00002018-199920020-00002 · Cited by 1,390
Sandborn, W. J., van Assche, G., Reinisch, W., Colombel, J., D’Haens, G., Wolf, D. C., Kron, M., Tighe, M. B., Lazar, A., & Thakkar, R. B. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.10.032 · Cited by 1,269
Self-citationRisk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Bloomgren, G., Richman, S., Hotermans, C., Subramanyam, M., Goelz, S., Natarajan, A., Lee, S., Plavina, T., Scanlon, J. V., Sandrock, A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1107829 · Cited by 1,242
D’Haens, G., Sandborn, W. J., Feagan, B. G., Geboes, K., Hanauer, S. B., Irvine, E. J., Lémann, M., Marteau, P., Rutgeerts, P., Schölmerich, J., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2006.12.038 · Cited by 1,207
Self-citation
Cited by
Ungaro, R., Mehandru, S., Allen, P. B., Peyrin-Biroulet, L., & Colombel, J.-F. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32126-2 · Cited by 3,531
Self-citationVedolizumab as Induction and Maintenance Therapy for Crohn's Disease
Sandborn, W. J., Feagan, B. G., Rutgeerts, P., Hanauer, S., Colombel, J.-F., Sands, B. E., Lukas, M., Fedorak, R. N., Lee, S., Bressler, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215739 · Cited by 2,719
Self-citationThe global burden of IBD: from 2015 to 2025
Kaplan, G. G. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.150 · Cited by 2,639
Lamb, C. A., Kennedy, N. A., Raine, T., Hendy, P. A., Smith, P. J., Limdi, J. K., Hayee, B., Lomer, M. C. E., Parkes, G. C., Selinger, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-318484 · Cited by 2,346
Peyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,844
Self-citationTofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
Sandborn, W. J., Su, C., Sands, B. E., D’Haens, G. R., Vermeire, S., Schreiber, S., Danese, S., Feagan, B. G., Reinisch, W., Niezychowski, W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606910 · Cited by 1,770
Self-citationKobayashi, T., Siegmund, B., Le Berre, C., Wei, S. C., Ferrante, M., Shen, B., Bernstein, C. N., Danese, S., Peyrin-Biroulet, L., & Hibi, T. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0205-x · Cited by 1,649
Self-citationLe Berre, C., Honap, S., & Peyrin-Biroulet, L. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00966-2 · Cited by 1,643
ACG Clinical Guideline: Ulcerative Colitis in Adults
Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G., & Long, M. D. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000152 · Cited by 1,577
Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., et al. (2012) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2012.09.002 · Cited by 1,548
Self-citationMoayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.001 · Cited by 1,499
de Lange, K. M., Moutsianas, L., Lee, J. C., Lamb, C. A., Luo, Y., Kennedy, N. A., Jostins, L., Rice, D. L., Gutierrez-Achury, J., Ji, S.-G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3760 · Cited by 1,445
Harbord, M., Eliakim, R., Bettenworth, D., Karmiris, K., Katsanos, K., Kopylov, U., Kucharzik, T., Molnár, T., Raine, T., Sebastian, S., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx009 · Cited by 1,180
The Human Gut Microbiome – A Potential Controller of Wellness and Disease
Kho, Z. Y., & Lal, S. K. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01835 · Cited by 1,104
ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment
Raine, T., Bonovas, S., Burisch, J., Kucharzik, T., Adamina, M., Annese, V., Bachmann, O., Bettenworth, D., Chaparro, M., Czuber-Dochan, W., et al. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab178 · Cited by 1,100
Rossen, N. G., Fuentes, S., van der Spek, M. J., Tijssen, J. G., Hartman, J. H. A., Duflou, A., Löwenberg, M., van den Brink, G. R., Mathus-Vliegen, E. M. H., de Vos, W. M., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.045 · Cited by 921
The safety of vedolizumab for ulcerative colitis and Crohn's disease
Colombel, J.-F., Sands, B. E., Rutgeerts, P., Sandborn, W., Danese, S., D'Haens, G., Panaccione, R., Loftus, E. V., Sankoh, S., Fox, I., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311079 · Cited by 806
Self-citationInflammatory Bowel Disease in Children and Adolescents
Rosen, M. J., Dhawan, A., & Saeed, S. A. (2015) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2015.1982 · Cited by 788
Cleynen, I., Boucher, G., Jostins, L., Schumm, L. P., Zeissig, S., Ahmad, T., Andersen, V., Andrews, J. M., Annese, V., Brand, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00465-1 · Cited by 779
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
Sands, B. E., Peyrin-Biroulet, L., Loftus, E. V., Danese, S., Colombel, J.-F., Törüner, M., Jonaitis, L., Abhyankar, B., Chen, J., Rogers, R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1905725 · Cited by 754
Self-citationZhao, J. H., Stacey, D., Eriksson, N., Macdonald-Dunlop, E., Hedman, Å. K., Kalnapenkis, A., Enroth, S., Cozzetto, D., Digby-Bell, J., Marten, J., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01588-w · Cited by 747
Ulcerative Colitis in Adults: A Review
Gros, B., & Kaplan, G. G. (2023) · JAMA · doi:10.1001/jama.2023.15389 · Cited by 738
Sands, B. E., Feagan, B. G., Rutgeerts, P., Colombel, J.-F., Sandborn, W. J., Sy, R., D’Haens, G., Ben-Horin, S., Xu, J., Rosario, M., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.05.008 · Cited by 715
Self-citationTargeting immune cell circuits and trafficking in inflammatory bowel disease
Neurath, M. F. (2019) · Nature Immunology · doi:10.1038/s41590-019-0415-0 · Cited by 701
Evidence-based clinical practice guidelines for inflammatory bowel disease
Matsuoka, K., Kobayashi, T., Ueno, F., Matsui, T., Hirai, F., Inoue, N., Kato, J., Kobayashi, K., Kobayashi, K., Koganei, K., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1439-1 · Cited by 698
Current and emerging therapeutic targets for IBD
Neurath, M. F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.208 · Cited by 691
Treatment of Inflammatory Bowel Disease: A Comprehensive Review
Cai, Z., Wang, S., & Li, J. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.765474 · Cited by 675
Danese, S., Vermeire, S., Zhou, W., Pangan, A. L., Siffledeen, J., Greenbloom, S., Hébuterne, X., D'Haens, G., Nakase, H., Panés, J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00581-5 · Cited by 643
Self-citationA comprehensive review and update on ulcerative colitis,
Gajendran, M., Loganathan, P., Jimenez, G., Catinella, A. P., Ng, N., Umapathy, C., Ziade, N., & Hashash, J. G. (2019) · Disease-a-Month · doi:10.1016/j.disamonth.2019.02.004 · Cited by 638
Immunological pathogenesis of inflammatory bowel disease
Lee, S. H., Kwon, J. E., & Cho, M.-L. (2018) · Intestinal Research · doi:10.5217/ir.2018.16.1.26 · Cited by 575
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
Nakase, H., Uchino, M., Shinzaki, S., Matsuura, M., Matsuoka, K., Kobayashi, T., Saruta, M., Hirai, F., Hata, K., Hiraoka, S., et al. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01784-1 · Cited by 505
Turner, D., Ruemmele, F. M., Orlanski‐Meyer, E., Griffiths, A. M., de Carpi, J. M., Bronsky, J., Veres, G., Aloi, M., Strisciuglio, C., Braegger, C. P., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002035 · Cited by 481
Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
Vermeire, S., O'Byrne, S., Keir, M., Williams, M., Lu, T. T., Mansfield, J. C., Lamb, C. A., Feagan, B. G., Panes, J., Salas, A., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60661-9 · Cited by 452
Self-citationOzanimod Induction and Maintenance Treatment for Ulcerative Colitis
Sandborn, W. J., Feagan, B. G., Wolf, D. C., D’Haens, G., Vermeire, S., Hanauer, S. B., Ghosh, S., Smith, H., Cravets, M., Frohna, P. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513248 · Cited by 452
Self-citationThe influence of cytokines on the complex pathology of ulcerative colitis
Nakase, H., Sato, N., Mizuno, N., & Ikawa, Y. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.103017 · Cited by 443
Paramsothy, S., Paramsothy, R., Rubin, D. T., Kamm, M. A., Kaakoush, N. O., Mitchell, H. M., & Castaño-Rodríguez, N. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx063 · Cited by 436
Bressler, B., Marshall, J. K., Bernstein, C. N., Bitton, A., Jones, J., Leontiadis, G. I., Panaccione, R., Steinhart, A. H., Tse, F., Feagan, B., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.03.001 · Cited by 413
Self-citationIntegrin-based therapeutics: biological basis, clinical use and new drugs
Ley, K., Rivera-Nieves, J., Sandborn, W. J., & Shattil, S. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.10 · Cited by 403
Self-citationFeuerstein, J. D., Moss, A. C., & Farraye, F. A. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.018 · Cited by 398
Bonovas, S., Fiorino, G., Allocca, M., Lytras, T., Nikolopoulos, G. K., Peyrin-Biroulet, L., & Danese, S. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.04.039 · Cited by 387
Self-citationLasa, J. S., Olivera, P. A., Danese, S., & Peyrin-Biroulet, L. (2022) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00377-0 · Cited by 384
Self-citationThe mucosal immune system: master regulator of bidirectional gut-brain communications
Powell, N., Walker, M. M., & Talley, N. J. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.191 · Cited by 379
Feuerstein, J. D., & Cheifetz, A. S. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.07.002 · Cited by 376
Singh, S., Murad, M. H., Fumery, M., Dulai, P. S., & Sandborn, W. J. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.01.008 · Cited by 375
Self-citationSandborn, W. J., Vermeire, S., Peyrin-Biroulet, L., Dubinsky, M. C., Panes, J., Yarur, A., Ritter, T., Baert, F., Schreiber, S., Sloan, S., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00061-2 · Cited by 365
Self-citationShah, S. C., Colombel, J.-F., Sands, B. E., & Narula, N. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.01.015 · Cited by 360
Self-citationReframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs
Schett, G., McInnes, I. B., & Neurath, M. F. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1909094 · Cited by 355
Newer Biologic and Small-Molecule Therapies for Inflammatory Bowel Disease
Baumgart, D. C., & Le Berre, C. (2021) · New England Journal of Medicine · doi:10.1056/nejmra1907607 · Cited by 354
Segal, J. P., LeBlanc, J.-F., & Hart, A. L. (2021) · Clinical Medicine · doi:10.7861/clinmed.2021-0080 · Cited by 351
Development and validation of a histological index for UC
Mosli, M. H., Feagan, B. G., Zou, G., Sandborn, W. J., D'Haens, G., Khanna, R., Shackelton, L. M., Walker, C. W., Nelson, S., Vandervoort, M. K., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-310393 · Cited by 350
Self-citationSandborn, W. J., Baert, F., Danese, S., Krznarić, Ž., Kobayashi, T., Yao, X., Chen, J., Rosario, M., Bhatia, S., Kisfalvi, K., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.08.027 · Cited by 331
Self-citationLeukocyte Trafficking to the Small Intestine and Colon
Habtezion, A., Nguyen, L. P., Hadeiba, H., & Butcher, E. C. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.10.046 · Cited by 315
Ihara, S., Hirata, Y., & Koike, K. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1350-1 · Cited by 302
COVID-19 and immunomodulation in IBD
Neurath, M. F. (2020) · Gut · doi:10.1136/gutjnl-2020-321269 · Cited by 302
Ulcerative colitis: Recent advances in the understanding of disease pathogenesis
Porter, R. J., Kalla, R., & Ho, G.-T. (2020) · F1000Research · doi:10.12688/f1000research.20805.1 · Cited by 300
Cholapranee, A., Hazlewood, G. S., Kaplan, G. G., Peyrin‐Biroulet, L., & Ananthakrishnan, A. N. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14030 · Cited by 296
Pathogenesis of Inflammatory Bowel Disease and Recent Advances in Biologic Therapies
Kim, D. H., & Cheon, J. H. (2017) · Immune Network · doi:10.4110/in.2017.17.1.25 · Cited by 295
Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
Sandborn, W. J., Ghosh, S., Panes, J., Schreiber, S., D’Haens, G., Tanida, S., Siffledeen, J., Enejosa, J., Zhou, W., Othman, A. A., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.02.030 · Cited by 289
Self-citationAn Overview of the Mechanism of Action of the Monoclonal Antibody Vedolizumab
Wyant, T., Fedyk, E., & Abhyankar, B. (2016) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjw092 · Cited by 284
Self-citationMitroulis, I., Alexaki, V. I., Kourtzelis, I., Ziogas, A., Hajishengallis, G., & Chavakis, T. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.11.008 · Cited by 283
Mitrev, N., Vande Casteele, N., Seow, C. H., Andrews, J. M., Connor, S. J., Moore, G. T., Barclay, M., Begun, J., Bryant, R., Chan, W., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14368 · Cited by 282
Gisbert, J. P., & Chaparro, M. (2020) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjz195 · Cited by 281
Ulcerative Colitis—Diagnostic and Therapeutic Algorithms
Kucharzik, T., Koletzko, S., Kannengießer, K., & Dignaß, A. (2020) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2020.0564 · Cited by 268
Agrawal, M., Spencer, E. A., Colombel, J.-F., & Ungaro, R. C. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.04.063 · Cited by 261
Self-citationIL-12 and IL-23 pathway inhibition in inflammatory bowel disease
Verstockt, B., Salas, A., Sands, B. E., Abraham, C., Leibovitzh, H., Neurath, M. F., Vande Casteele, N., Alimentiv Translational Research Consortium (ATRC), Danese, S., D’Haens, G., et al. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00768-1 · Cited by 261
Self-citationAnti-commensal IgG Drives Intestinal Inflammation and Type 17 Immunity in Ulcerative Colitis
Castro-Dopico, T., Dennison, T. W., Ferdinand, J. R., Mathews, R. J., Fleming, A., Clift, D., Stewart, B. J., Jing, C., Strongili, K., Labzin, L. I., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.02.006 · Cited by 248
A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers
Fidelle, M., Rauber, C., Alves Costa Silva, C., Tian, A.-L., Lahmar, I., de La Varende, A.-L. M., Zhao, L., Thelemaque, C., Lebhar, I., Messaoudene, M., et al. (2023) · Science · doi:10.1126/science.abo2296 · Cited by 243
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, V., Hertervig, E., Gedeon, P., Kopljar, M., Griph, H., Kinhult, S., Carneiro, A., & Marsal, J. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1962-6 · Cited by 234
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Abu-Sbeih, H., Ali, F. S., Alsaadi, D., Jennings, J., Luo, W., Gong, Z., Richards, D. M., Charabaty, A., & Wang, Y. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0461-4 · Cited by 215
Kump, P., Wurm, P., Gröchenig, H. P., Wenzl, H., Petritsch, W., Halwachs, B., Wagner, M., Stadlbauer, V., Eherer, A., Hoffmann, K. M., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14387 · Cited by 196
NAD metabolism fuels human and mouse intestinal inflammation
Gerner, R. R., Klepsch, V., Macheiner, S., Arnhard, K., Adolph, T. E., Grander, C., Wieser, V., Pfister, A., Moser, P., Hermann-Kleiter, N., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314241 · Cited by 192
Abu-Sbeih, H., Ali, F. S., Wang, X., Mallepally, N., Chen, E., Altan, M., Bresalier, R. S., Charabaty, A., Dadu, R., Jazaeri, A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0577-1 · Cited by 191
Hildebrand, T., Pannicke, N., Dechene, A., Gotthardt, D. N., Kirchner, G., Reiter, F. P., Sterneck, M., Herzer, K., Lenzen, H., Rupp, C., et al. (2016) · Liver Transplantation · doi:10.1002/lt.24350 · Cited by 162
Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis
Kreuger, J., & Phillipson, M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.2 · Cited by 160
Recipient factors in faecal microbiota transplantation: one stool does not fit all
Danne, C., Rolhion, N., & Sokol, H. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00441-5 · Cited by 154
Next generation of small molecules in inflammatory bowel disease
Olivera, P., Danese, S., & Peyrin-Biroulet, L. (2017) · Gut · doi:10.1136/gutjnl-2016-312912 · Cited by 154
Self-citationT lymphocytes in the intestinal mucosa: defense and tolerance
Ma, H., Tao, W., & Zhu, S. (2019) · Cellular & Molecular Immunology · doi:10.1038/s41423-019-0208-2 · Cited by 125
Ma, C., Sedano, R., Almradi, A., Vande Casteele, N., Parker, C. E., Guizzetti, L., Schaeffer, D. F., Riddell, R. H., Pai, R. K., Battat, R., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.02.035 · Cited by 105
Self-citationLynch, K. D., Chapman, R. W., Keshav, S., Montano-Loza, A. J., Mason, A. L., Kremer, A. E., Vetter, M., de Krijger, M., Ponsioen, C. Y., Trivedi, P., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2019.05.013 · Cited by 105
Blockade of IL-23: What is in the Pipeline?
Parigi, T. L., Iacucci, M., & Ghosh, S. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjab185 · Cited by 93
Sivro, A., Schuetz, A., Sheward, D., Joag, V., Yegorov, S., Liebenberg, L. J., Yende-Zuma, N., Stalker, A., Mwatelah, R. S., Selhorst, P., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam6354 · Cited by 94
Christensen, B., Micic, D., Gibson, P. R., Yarur, A., Bellaguarda, E., Corsello, P., Gaetano, J. N., Kinnucan, J., Rao, V. L., Reddy, S., et al. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14525 · Cited by 91
“Median duration of PSC, y (IQR) 8 (3-10) 3 (1-8)”
Interventions for fatigue in inflammatory bowel disease
Farrell, D., Artom, M., Czuber-Dochan, W., Jelsness-Jørgensen, L. P., Norton, C., & Savage, E. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012005.pub2 · Cited by 89
Resolution of inflammation in inflammatory bowel disease
Rogler, G. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30031-6 · Cited by 79
Inflammatory bowel disease – non-biological treatment
Magro, F., Cordeiro, G., Dias, A. M., & Estevinho, M. M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105075 · Cited by 77
Inflammatory Bowel Disease: Emerging Therapies and Future Treatment Strategies
Bretto, E., Ribaldone, D. G., Caviglia, G. P., Saracco, G. M., Bugianesi, E., & Frara, S. (2023) · Biomedicines · doi:10.3390/biomedicines11082249 · Cited by 58
Nowak, J. K., Adams, A. T., Kalla, R., Lindstrøm, J. C., Vatn, S., Bergemalm, D., Keita, Å. V., Gomollón, F., Jahnsen, J., Vatn, M. H., et al. (2022) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjac033 · Cited by 51
Induction of a colitogenic phenotype in Th1-like cells depends on interleukin-23 receptor signaling
Pawlak, M., DeTomaso, D., Schnell, A., Meyer zu Horste, G., Lee, Y., Nyman, J., Dionne, D., Regan, B. M. L., Singh, V., Delorey, T., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.08.007 · Cited by 49
Timing, management, and outcomes of liver transplantation in primary sclerosing cholangitis
Levy, C., & Martin, E. (2017) · Seminars in Liver Disease · doi:10.1055/s-0037-1608655 · Cited by 46
Long-term safety of approved biologics for ulcerative colitis
D’Amico, F., Parigi, T. L., Bonovas, S., Peyrin-Biroulet, L., & Danese, S. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1773430 · Cited by 29
Self-citationSafety of vedolizumab in liver transplant recipients: a systematic review
Spadaccini, M., Aghemo, A., Caprioli, F., Lleo, A., Invernizzi, F., Danese, S., & Donato, M. F. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619858050 · Cited by 20
Self-citation
Metadata
- Authors
- Feagan, B. G., Rutgeerts, P., Sands, B. E., Hanauer, S., Colombel, J.-F., Sandborn, W. J., Van Assche, G., Axler, J., Kim, H.-J., Danese, S., Fox, I., Milch, C., Sankoh, S., Wyant, T., Xu, J., & Parikh, A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-22
- Volume
- 369
- Issue
- 8
- Pages
- 699-710
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2162805528
- Cited by
- 2,888
- References
- 32
- FWCI
- 90.44
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.